導管靜脈造影證實顱靜脈出血的相當顯著的不對稱，左側顯性。存在輕度顱內靜脈高壓（中矢狀竇壓力，22cm H 2 O），中間矢狀竇和右心房之間具有5cm H 2 O壓力梯度，包括在每側頸靜脈狹窄處的局灶性3cm H 2 O壓力梯度。
腰椎穿刺給予18cm H 2 O的開啟壓力。
Axial postcontrast computed tomography at the level of the C1 vertebra. The right jugular vein is rendered invisible behind the right styloid process (long arrow). The left jugular vein (large arrow) is less severely narrowed behind the left styloid...(圖2) 第一頸椎附近的左右內頸靜脈MRI圖，左內頸靜脈(短箭頭處)比右內頸靜脈明顯小很多，證明窄化...
我們描述的病人就是一個例子。雖然頭痛不存在，他的其他症狀是典型的顱內低血壓，並且成像確認後腦的明顯塌陷，然而腰椎穿刺顯示CSF打開壓力為18cm H 2 O，即，在正常範圍內。那麼，患者可能出現的顱內低血壓的症狀和放射學發現，包括腦脊液漏，但具有正常的腦脊液壓力，怎麼樣？不可能設想CSF洩漏將不會降低CSF壓力。因此，這些患者必須具有在前症狀的CSF壓力高於當它們變得有症狀時測量的CSF壓力。
A multiple sclerosis patient from
Saskatchewan who travelled to India to undergo an experimental stem cell
treatment is defending the Winnipeg company that recruited her for the
therapy and study, which some have called into question.
Regenetek Research has been under scrutiny following media reports this week about its CEO, Doug Broeska.
Broeska had recruited MS patients
to take part in the experimental and expensive study, which was
administered in India, involving stem cell injections combined with
so-called liberation therapy, which involves the widening of veins in
the neck.
He was, until recently, also the principal researcher for the study related to the treatment.
However, some patients have questioned Broeska's qualifications as a
researcher. As well, some say the therapy did not work for them, and
they were not receive proper followup.
Other patients, like Linda Friesen of Tisdale, Sask., reported having success with the therapy.
"I am shocked right now. I am surprised in what has been said," she told CBC News when asked about the latest allegations.
Friesen said she used to rely on a wheelchair because of her MS and
injuries from a car accident, but she left that wheelchair behind at the
hospital in India after undergoing the experimental treatment — which
cost her $34,000 US — in 2013.
"It's so amazing to have this opportunity to be part of the research," she said in a promotional video produced by Regenetek.
Friesen told CBC News that the company has paid her to help other MS patients in Saskatchewan with their paperwork.
另一位病患 Linda Friesen 則被報導是一個成功的案例。
"聽到那個質疑讓我很震驚"，她過去需要倚賴輪椅(因為MS和一場車禍)，但是在2013年去了印度花了3萬4千美元做這個手術之後，就不需要輪椅了。能參與這個研究很棒。
Regenetek responds
In a statement issued Thursday, Regenetek Research says its stands
behind its role in the stem cell therapy study, "namely as researchers
tracking participant progress following medical treatment, with such
medical treatment having been provided by third-party medical
practitioners located in India.
"Regenetek Research and its researchers do not provide medical
treatment in connection with the clinical study," the company's
statement reads in part.
"Further, the study was never intended to replace other medical
treatment and individuals were directed to stay in contact with their
treating physicians. We are scientists simply tracking the progress of
participants who have chosen to attempt innovative therapy options and
to have their results noted by us for scientific study."
Winnipeg-based
Regenetek Research issued a statement Thursday in response to media
reports about Doug Broeska, who had recruited MS patients to take part
in the experimental and expensive study involving stem cell injections
combined with so-called liberation therapy. (CBC)
Last
month, the ethics committee with the hospital in India where the
treatment was being performed ordered Broeska to step down as principal
investigator, saying his lack of credentials and medical followup
"violated international ethical standards."
Broeska had stated on a LinkedIn profile that he has a PhD from the
University of Manitoba, but the university confirmed that neither a Doug
Broeska nor a Henry Douglas Broeska graduated from there. The profile
has since been removed from the site.
The International Cellular Medicine Society and the College of
Physicians and Surgeons of Manitoba both said they have no record of
Broeska as a member.
Broeska has not responded to requests from CBC News for an interview.
The company's statement was not signed by him, and it does not directly
address specific questions about his credentials.
Broeska has defended his qualifications to another media outlet and in emails to patients.
In one message, obtained by CBC News, he told a patient that his
credentials are sound and he is "competent to perform research of this
type."
Experts concerned about fallout
Meanwhile, some in the scientific community say they're worried that
the fallout from this and other controversies could result in confusion
about stem cell research as a whole.
Dr. Duncan Stewart of the Ottawa Hospital Research Institute, which
is conducting research on using genetically enhanced stem cells to
repair damaged heart muscle, said the field is in its early days and has
tremendous promise.
"It only takes one high-profile significant problem to make everyone very nervous," he said.
Tim Caulfield, the Canada Research Chair in Health Law and Policy at the University of Alberta, agrees.
"That's a really good example of how the availability of these
treatments, marketing of these treatments, can lead people to believe
stem cell therapy is much further along than it really is," he said.
The Canadian Stem Cell Foundation says it wants the federal
government to invest $50 million in stem-cell research in each of the
next 10 years.
It also wants Ottawa to streamline the process for clinical trials in
this country "so that Canadians that are suffering have access to
treatments that are safe and proven to be effective," said James Price,
the foundation's president and CEO.
Lee Chuckry, 47, of Airdrie, Alta., said he spent $34,000 for the therapy only to find out his MS has worsened.
"I think it's just a big fraudulent scam," he told CBC News on Wednesday.
Chuckry, who has been battling MS for over a decade, said the
treatment involved the widening of the veins in his neck — a practice
advocates call liberation therapy — plus the injection of stem cells
into his veins and spinal column.
Lee
Chuckry of Airdrie, Alta., says he was recruited to undergo
experimental stem cell therapy in India. After travelling there and
spending $34,000 on the treatment, Chuckry says he believes his MS has
worsened. (CBC)
發表文章
